In Vivo PET Detection of Lung Micrometastasis in Mice by Targeting Endothelial VCAM-1 Using a Dual-Contrast PET/MRI...

Area of Science:

• Biomedical Imaging
• Oncology
• Nanotechnology

Background:

• Current lung metastasis imaging lacks sensitivity for early-stage micrometastases.
• Antibody-targeted microparticles of iron oxide (MPIO) can image vascular cell adhesion molecule-1 (VCAM-1).

Purpose of the Study:

• To develop a dual-modality (PET/MRI) contrast agent for sensitive in vivo detection of lung micrometastases.
• To enable early diagnosis and improve treatment outcomes for metastatic lung cancer.

Main Methods:

• Modification of VCAM-MPIO with zirconium-89 (89Zr) to create 89Zr-DFO-VCAM-MPIO for PET imaging.
• Utilizing a mouse model of lung metastasis to evaluate the agent's efficacy.
• Histological analysis and autoradiography to confirm specific binding to VCAM-1 expressing vasculature.

Main Results:

• The 89Zr-DFO-VCAM-MPIO agent successfully detected lung micrometastases as small as 140 μm in vivo.
• Specific binding of the agent to VCAM-1 positive vasculature at metastatic sites was confirmed.
• The agent facilitates dual-modality PET/MRI for concurrent detection of lung and brain micrometastases.

Conclusions:

• A novel 89Zr-labeled VCAM-targeted MPIO agent enables highly sensitive PET/MRI detection of lung micrometastases.
• This dual-modality approach significantly improves early cancer detection capabilities.
• The developed agent holds promise for improved diagnosis and management of metastatic disease.